Cascorbi I, Schwab M
Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
Clin Pharmacol Ther. 2016 May;99(5):468-70. doi: 10.1002/cpt.349.
Hereditary genetic variation has been identified to contribute significantly to drug response. More recently, there is increasing evidence that individual phenotypic differences may also result from epigenetic alterations such as histone-acetylation or DNA-methylation. Moreover, interactions with noncoding RNAs contribute to protein expression and may modulate drug action. Currently, intriguing developments of novel therapeutic approaches through epigenetic drugs are emerging. The overall complexity of epigenetics in drug action, however, is so far only little understood.
遗传性基因变异已被证实对药物反应有显著影响。最近，越来越多的证据表明，个体表型差异也可能源于表观遗传改变，如组蛋白乙酰化或DNA甲基化。此外，与非编码RNA的相互作用有助于蛋白质表达，并可能调节药物作用。目前，通过表观遗传药物开发新型治疗方法的有趣进展正在出现。然而，表观遗传学在药物作用中的整体复杂性至今仍知之甚少。
